$12.59
1.33% day before yesterday
Nasdaq, Nov 28, 07:00 pm CET
ISIN
US04335A1051
Symbol
ARVN

Arvinas, Inc. Stock price

$12.59
+3.09 32.47% 1M
+5.30 72.75% 6M
-6.59 34.35% YTD
-13.40 51.56% 1Y
-26.40 67.71% 3Y
-11.62 48.00% 5Y
-3.47 21.59% 10Y
-3.47 21.59% 20Y
Nasdaq, Closing price Fri, Nov 28 2025
+0.17 1.33%
ISIN
US04335A1051
Symbol
ARVN
Industry

Key metrics

Basic
Market capitalization
$808.3m
Enterprise Value
$21.1m
Net debt
positive
Cash
$787.6m
Shares outstanding
70.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
2.6 | 3.1
EV/Sales
0.1 | 0.1
EV/FCF
negative
P/B
1.4
Financial Health
Equity Ratio
51.5%
Return on Equity
-35.4%
ROCE
-14.6%
ROIC
192.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$312.3m | $259.6m
EBITDA
$-98.5m | $-83.7m
EBIT
$-101.9m | $-138.2m
Net Income
$-58.4m | $-87.8m
Free Cash Flow
$-329.4m
Growth (TTM | estimate)
Revenue
10.5% | -1.5%
EBITDA
83.3% | 65.9%
EBIT
82.8% | 44.8%
Net Income
88.8% | 55.9%
Free Cash Flow
-26.8%
Margin (TTM | estimate)
Gross
-
EBITDA
-31.5% | -32.2%
EBIT
-32.6%
Net
-18.7% | -33.8%
Free Cash Flow
-105.5%
More
EPS
$-0.8
FCF per Share
$-4.7
Short interest
12.9%
Employees
430
Rev per Employee
$610.0k
Show more

Is Arvinas, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Arvinas, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Arvinas, Inc. forecast:

15x Buy
58%
10x Hold
38%
1x Sell
4%

Analyst Opinions

26 Analysts have issued a Arvinas, Inc. forecast:

Buy
58%
Hold
38%
Sell
4%

Financial data from Arvinas, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
312 312
10% 10%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 107 107
54% 54%
34%
- Research and Development Expense 307 307
52% 52%
98%
-99 -99
83% 83%
-32%
- Depreciation and Amortization 3.40 3.40
28% 28%
1%
EBIT (Operating Income) EBIT -102 -102
83% 83%
-33%
Net Profit -58 -58
89% 89%
-19%

In millions USD.

Don't miss a Thing! We will send you all news about Arvinas, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arvinas, Inc. Stock News

Neutral
GlobeNewsWire
3 days ago
NEW HAVEN, Conn., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, and Andrew Saik, Chief Financial Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference o...
Neutral
GlobeNewsWire
5 days ago
NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that multiple abstracts on vepdegestrant (ARV-471) have been accepted for presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS), taking place December 9–12, 2025 in San Ant...
Neutral
Seeking Alpha
24 days ago
Arvinas, Inc. ( ARVN ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Jeff Boyle - Vice President of Investor Relations John Houston - Chairperson, CEO & President Noah Berkowitz - Chief Medical Officer Angela Cacace - Chief Scientific Officer Andrew Saik - CFO & Treasurer Conference Call Participants Etzer Darout - Barclays Bank PLC, Research Division Jeet Mukherjee - ...
More Arvinas, Inc. News

Company Profile

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.

Head office United States
CEO John Houston
Employees 430
Founded 2013
Website www.arvinas.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today